{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7"},{"groupId":"OG001","value":"90.7"},{"groupId":"OG002","value":"90.5"},{"groupId":"OG003","value":"84.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"7071"},{"groupId":"OG002","value":"305"},{"groupId":"OG003","value":"7078"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.","groups":[{"description":"V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.","id":"OG000","title":"Low-dose V503"},{"description":"V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.","id":"OG001","title":"Mid-dose V503"},{"description":"V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.","id":"OG002","title":"High-dose V503"},{"description":"Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.","id":"OG003","title":"Gardasil"}],"paramType":"NUMBER","populationDescription":"The analysis population included all participants who received \\>=1 vaccination and had safety follow-up","reportingStatus":"POSTED","timeFrame":"Up to Day 5 after any vaccination","title":"Base Study: Percentage of Participants With One or More Injection-site Adverse Event","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}